SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion
Pathology - Research and Practice · 2025
DOI: 10.1016/j.prp.2025.155975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2025. Verfasst von Gang Fu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, 197 Ruijin 2nd Road, Shanghai, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Cell Proliferation, Colorectal Neoplasms, Tumor Escape. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Shanghai Jiao Tong University, Shanghai Anti-Cancer Association, National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Cancer cells often evade immune responses by overexpressing immune checkpoint regulators, such as programmed cell death ligand 1 (PD-L1). Identifying targets that regulate PD-L1 is a promising approach for anti-tumor therapy. METHODS: Based on our previous CRISPR-Cas9 screening, we identified SMARCD1, a subunit of the mating-type switching/sucrose fermentation (SWI/SNF) complex, as a factor that promotes tumor evasion by inducing PD-L1-mediated immune checkpoint responses. Immunohistochemical staining (IHC) was used to assess SMARCD1 expression levels in colorectal cancer (CRC) and normal tissues. CRISPR-Cas9 technology was employed to generate SMARCD1 knockout (KO) cell lines. Western blotting and flow cytometry were used to evaluate PD-L1 expression. Cell proliferation, invasion, migration, and apoptosis were also assessed. A tumor model was established to examine the in vivo effects of SMARCD1. RNA-seq and ChIP-seq analyses were conducted to investigate the potential mechanisms. RESULTS: SMARCD1 was significantly upregulated in CRC tissues. In vitro, SMARCD1 regulated PD-L1 expression and significantly promoted tumor growth. The SWI/SNF inhibitor FHT-1015 reversed the effects of SMARCD1 knockout. Mechanistically, SMARCD1 may maintain chromatin accessibility at the PD-L1 transcriptional regulatory element and promote cancer cell proliferation via the PI3K-Akt signaling pathway. CONCLUSION: SMARCD1 regulates PD-L1 transcription and facilitates tumor cell proliferation, making it a promising target for CRC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, 197 Ruijin 2nd Road, Shanghai, China.
- The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
- Department of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, 197 Ruijin 2nd Road, Shanghai, China. Electronic address: yongsmith@163.com.
- Department of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, 197 Ruijin 2nd Road, Shanghai, China. Electronic address: mmc683@126.com.
- Department of General Surgery, Shanghai Jiao Tong University School of Medicine affiliated Ruijin Hospital, 197 Ruijin 2nd Road, Shanghai, China. Electronic address: caiwei@shsmu.edu.cn.
Förderung
- Shanghai Jiao Tong University
- Shanghai Anti-Cancer Association
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
- Anticancer Fund
Zitieren
APA
Fu, G., Liu, Y., Qian, C., Yang, Z., Luo, M., & Cai, W. (2025). SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.155975
Vancouver
Fu G, Liu Y, Qian C, Yang Z, Luo M, Cai W. SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion. Pathology - Research and Practice. 2025. doi:10.1016/j.prp.2025.155975
BibTeX
@article{Fu2025,
author = {Fu, Gang and Liu, Yutong and Qian, Chen and Yang, Zheyu and Luo, Maocai and Cai, Wei},
title = {SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion},
journal = {Pathology - Research and Practice},
year = {2025},
doi = {10.1016/j.prp.2025.155975}
}
EUVIMED